Interleukin-2-based therapy for metastatic renal cell cancer: The cytokine working group experience, 1989-1997

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Dutcher, Janice P ^a   Atkins, Michael ^b   Fisher, Richard ^c   Weiss, Geoffrey ^d   Margolin, Kim ^e   Aronson, Fred ^f   Sosman, Jeffrey ^c   Lotze, Michael ^g   Gordon, Michael ^h   Logan, Theodore ^g   Mier, James ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h INDIANA UNIVERSITY   (United States)

Author keywords

Interferon; Interleukin 2; Renal cell cancer

Indexed keywords

FLUOROURACIL; INTERLEUKIN 2; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NEUROTOXICITY; OLIGURIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031424976     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13: 688-696.
2. Fyfe GA, Fisher RI, Rosenberg SA et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14:2410-2411.
3. Atzpodien J, Hanninen EL, Kirchner H et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon-alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 1995;13:497-501.
4. Figlin RA, Belldegrun A, Moldawer N et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2a: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992;10:414-421.
5. Dutcher JP, Fisher RI, Weiss G et al. An outpatient (OPT) regimen of subcutaneous (SC) interleukin-2 (IL2) plus alpha-interferon (IFN) in metastatic renal cell cancer (RCC). Proceedings of ASCO 1993;12:248.
6. Dutcher JP, Fisher RI, Weiss G et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157-162.
7. Dutcher JP, Logan T, Gordon M et al. 5FU + subcutaneous (SC) interleukin-2 (IL2) plus SC Intron (IFN) in metastatic renal cell cancer (RCC) patients (PTS): a CWG study. Proceedings of ASCO 1996;15:272.
8. Margolin K, Rayner AA, Hawkins MJ et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486-498.
9. Gitlitz BJ, Pierce W, Moldawer N et al. Long term follow-up and patterns of relapse in metastatic renal cell carcinoma (RCCA) using an outpatient regimen of low-dose interleukin-2 (IL-2) and interferon-alpha (IFN): UCLA kidney cancer program. Proceedings of ASCO 1994;13:802a.
10. Yang JC, Topalian SL, Parkinson D et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994;12:1572-1576.
11. Yang JC, Rosenberg S. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 1997;3[suppl 1]:S79-S84.
12. Atkins MB, Sparano J, Fisher RI et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993;11:661-670.
13. Dutcher J, Atkins M, Fisher R et al. IL-2-based therapy in metastatic renal cell cancer (MRCC): Cytokine Working Group (CWG) experience. Proceedings of ASCO 1997;16:327a.
14. Atzpodien J, Kirchner H, Hanninen EL et al. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993;29A[suppl 5]:S6-S8.
15. Dutcher J, Atkins M, Fisher R et al. IL-2-based therapy in metastatic renal cell cancer (MRCC): Cytokine Working Group experience [poster]. Presented at the Thirty-Third Annual Meeting of the American Society of Clinical Oncology; May 17-20, 1997; Denver, CO.
16. Negrier S, Escudier B, Lasset C et al. The FNCLCC CRECY TRIAL: interleukin-2 (IL2) + interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC). Proceedings of ASCO 1996;15:629a.